MADEW

ULDEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY DCKET NO. 207596

APPLICATION NO. 09/720,276

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT Erickson et al.

MAR 2 6 7001 (Use several sheets if necessary)

FILING DATE December 21, 2000

GROUP

Unassigned 1648

		· ·	
U.S.	PATENT	DOCUMENTS	

		·									
			APPLICATION]						FILIN	G DATE
Exa	MINER'S		OR PATENT								IF
In	ITIALS		Number	Issue Date	NAME	Cı	LASS	SUB	CLASS	APPR	OPRIATE
ele		AA	5,766,842	06/16/1998	Heefner et al.				1		-
		AB 、	5,753,660	05/19/1998	Sikorski et al.						
	:	AC	5,728,718	03/17/1998	Randad et al.						
		AD	5,723,490	03/03/1998	Tung						
		AE	5,705,500	01/06/1998	Getman et al.						
		AF	5,703,076	12/30/1997	Talley et al.						
	-	AG	5,502,060	3/26/1996	Thompson						
		AH	5,475,027	12/12/1995	Talley et al.						

FOREIGN PATENT DOCUMENTS

			DOCUMENT	PUBLICATION				TRANS	LATION
			Number	DATE	Country	CLASS	SUBCLASS	YES	No*+
ela	1-	AI ·	WO 99/67417	12/29/1999	WIPO	Ţ	1	1	,
	\	AJ	WO 99/67254	12/29/1999	WIPO	- 1			
	1	AK	WO 99/65870	12/23/1999	WIPO				
A.	/-	AL,	WO 97/19055	05/29/1997	WIPO				
	4.	AM	WO 96/28463	09/16/1996	WIPO				
	7-	AN	WO 95/06030	03/02/1995	WIPO				
	6	-AO	2,276,621	10/05/1994	UK				
	/-	-AP	WO 94/14793	07/07/1994	WIPO				
	$\overline{}$	AQ	WO 94/05639	03/17/1994	WIPO	,			
	\	AR_	WO 94/04492	03/03/1994	WIPO		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
	7	AS	WO 90/09191	08/23/1990	WIPO NT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

\=	 AT_	Rone et al., I. Am. Chem. Soc., 113, 9382 (1991)
ele /	AU	Borman et al., J. Gen. Virology, 77(3), 419-426 (March 1996)
	AV	Erickson et al., Science, 249, 527-533 (1990)
	AW	Ghosh et al., Bioorganic & Medicinal Chemistry Letters, 8, 687-690 (March-1998)
	AX	Ghosh et al., J. Medicinal Chemistry, 36(16), 2300-2310 (August 1993)
	AY	Ghosh et al., J. Medicinal Chemistry, 36(2), 292-294 (January 1993)
	AZ	Ghosh et al., J. Medicinal Chemistry, 37(16), 2506-2508 (August 1994)
	ВА	Ghosh et al., J. Medicinal Chemistry, 37, 1177-1188 (April 1994)
	BB	Gulnik et al., Biochemistry, 34(29), 9282-9287 (July 1995)
	BC	Ho ct al., J. Virology, 68(3), 2016-2020 (March 1994)
	BD	Huff, J. Med. Chem., 34(8), 2305-2314 (August 1991)
	BE	Kageyama et al., Antimicrob Agents Chemother., 36, 926-933 (May 1992)
-	BF	Kaplan er al., PNAS USA, 91, 5397-3601 (1994)

FORM PTO-1449
MODIFIED

UR DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY OCKET NO. 207596

APPLICATION NO. 09/720,276

MAR 2 6 2000

SYNFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Erickson et al.

(Use several sheets if necessary)

FILING DATE
December 21, 2000

GROUP
Unassigned 1649

		December 21, 2000 Ghassighed 10 1
	BG	Kim et al., J. Medicinal Chemistry, 38(17), 1181-1182 (1995)
/	BH _	Klabe et al., Biochemistry, 37(24), 8735-8742 (May 1998)
٩	BI	Kramer et al., Science, 231, 1580-1584 (1996)
	BJ	Lyle et al., J. Med. Chem., 34(3), 1228-1230 (March 1991)
₹	BK	Majer et al., 13th American Peptide Symposium, Edmonton, Canada (1993)
7	BL	Martinez-Picado et al. J. Virology, 73(5), 3744-3752 (May 1999)
1	BM-	MeQuade et al., Science, 247, 454-456 (1990)
${\downarrow}$	BN	Meck et al., Nature, 343(6253), 90-92 (January 1990)
\rightarrow		Meek, J. Enzyme Inhibition, 6(1), 65-98 (January 1992)
	,	Moore et al., Perspect: Drug Dis. Design, 1, 85-108 (1993)
<u>`</u>		Norbeck et al., Ann. Reports Med. Chem., 26, 141-150 (1991)
		Otto et al., PNAS USA, 90, 7543-7547 (1993)
1	БЗ	Plattner et al., Drug Discovery Technologies, Clark et al., eds., Ellish Horwood, Chichester, England, 92-12 (1990)
7	BT	Rich ét al., J. Med. Chem., 33(5), 1285-1288 (May 1990)
	BU	Roberts et al., Science, 248, 358-361 (1990)
	BV	Tomasselli et al., Int. J. Chem. Biotechnology, 6, 6-27 (1991)
1	DW	Vacca et al., J. Med. Chem., 34(3), 1225-1228 (March 1991)
1	BX	Vazquez et al., J. Medicinal Chemistry, 38(4), 581-584 (February 1995)
~		1. DATE CONSIDERED
		BG BH BI BJ BK BL

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(b).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(b).